Evolution of ADME science: Where else can modeling and simulation contribute?

Molecular Pharmaceutics

Volumn 10, Issue 4, 2013, Pages 1162-1170

  Smith, Dennis A ^a,b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

antibody drug conjugates; CYP450; hepatotoxicity; metabolites; permeability; PSA; TPSA; transporters

Indexed keywords

ANTIBODY CONJUGATE; BETAXOLOL; BOSENTAN; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DESACETYLLORATIDINE; DOLASETRON MESILATE; DRUG METABOLITE; DRUG METABOLIZING ENZYME; FENFLURAMINE; FLUTAMIDE; HYDRODOLASETRON; HYDROXYFLUTAMIDE; LORATADINE; METOPROLOL; NORFENFLURAMINE; NORSIBUTRAMINE; NORTRAMADOL; NORZOLMITRIPTAN; PRODRUG; PROPRANOLOL; RO 478634; RO 485033; SIBUTRAMINE; TALINOLOL; TRAMADOL; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOLMITRIPTAN;

ACTIVE TRANSPORT; CLASSIFICATION; COMPUTER MODEL; DIFFUSION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISPOSITION; DRUG EXCRETION; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; DRUG SOLUBILITY; DRUG SYNTHESIS; DRUG TRANSPORT; HUMAN; INTERMETHOD COMPARISON; LIVER TOXICITY; MEMBRANE PERMEABILITY; MOLECULAR MODEL; NONHUMAN; PASSIVE TRANSPORT; PHYSICAL CHEMISTRY; PREDICTION; PRIORITY JOURNAL; QUALITY CONTROL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; SIMULATION;

CHEMISTRY, PHARMACEUTICAL; CHEMISTRY, PHYSICAL; COMPUTER SIMULATION; DRUG DESIGN; DRUG DISCOVERY; HEPATOCYTES; HUMANS; MICROSOMES, LIVER; MODELS, THEORETICAL; REPRODUCIBILITY OF RESULTS; SOFTWARE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84875781502     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp3005319     Document Type: Review

References (32)

1. Smith, D. A. Hello Drug Discovery, I am from Insilico, take me to your President Drug Discovery Today 2002, 7 (21) 1080-1081
2. Ito, K.; Houston, J. B. Comparison of the Use of Liver Models for Predicting Drug Clearance Using in Vitro Kinetic Data fro m Hepatic Microsomes and Isolated Hepatocytes Pharm. Res. 2004, 21 (5) 785-792
3. Amidon, G. L; Lennernas, H.; Shah, V.; Crison, J. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability Pharm. Res. 1995, 12 (3) 213-220
4. Wu, C. Y.; Benet, L. Z. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a Biopharmaceutics Drug Disposition Classification System Pharm. Res. 2005, 22 (1) 11-23
5. Chen, M.-L.; Amidon, G. L.; Benet, L. Z.; Lennernas, H.; Yu, L. X. The BCS, BDDCS, and Regulatory Guidances Pharm. Res. 2011, 28 (7) 1774-1778
6. Stenberg, P.; Kristina Luthman, K.; Per Artursson, P. Virtual screening of intestinal drug permeability J. Controlled Release 2000, 65 (1-2) 231-243
7. Broccatelli, F.; Crucianii, G.; Oprea, T. I. BDDCSApplied to over 900 drugs AAPS J. 2011, 14 (4) 519-547
8. Benet, L. Z.; Broccatelli, F.; Cruciani, G.; Oprea, T. I. BDDCS Class predictions for new molecular entities Mol. Pharmaceutics 2012, 9 (3) 570-580
9. Beaumont, K.; Schmid, E.; Smith, D. A. Oral delivery of G protein-coupled receptor modulators: An explanation for the observed class difference Bioorg. Med. Chem. Lett. 2005, 15 (16) 3658-3664
10. Hakkarainen, J. J.; Pajander, J.; Laitinen, R.; Suhonen, M.; Forsberg, M. M. Similar molecular descriptors determine the in vitro drug permeability in endothelial and epithelial cells Int. J. Pharm. 2012, 436 (1-2) 426-443
11. Clark, D. E. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena 1. Prediction of intestinal absorption J. Pharm. Sci. 1999, 88 (8) 807-814
12. Erte, P.; Rohde, B.; Selzer, P. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties J. Med. Chem. 2000, 43 (20) 3714-3717
13. Alex, A.; Millan, D. S.; Perez, M.; Wakenhut, F.; Whitlock, G. A. Intramolecular hydrogen bonding to improve membrane permeability and absorption in beyond rule of five chemical space Med Chem. Commun. 2011, 2 (7) 669-674
14. Paine, S. W.; Parker, A. J.; Gardiner, P.; Webborn, P. J. H.; Riley, R. J. Prediction of the Pharmacokinetics of Atorvastatin, Cerivastatin, and Indomethacin Using Kinetic Models Applied to Isolated Rat Hepatocytes Drug Metab. Dispos. 2008, 36 (7) 1365-1374
15. Hallifax, D.; Houston, J. B. Binding Of Drugs To Hepatic Microsomes: Comment And Assessment Of Current Prediction Methodology With Recommendation For Improvement Drug Metab. Dispos. 2006, 34 (4) 724-726
16. Gao, H.; Yao, L.; Mathieu, H. W.; Zhang, Y.; Maurer, T. S.; Troutman, M. D.; Scott, D. O.; Ruggeri, R. B.; Lin, J. In Silico Modeling of Nonspecific Binding to Human Liver Microsomes Drug Metab. Dispos. 2008, 36 (10) 2130-2135
17. Smith, D. A.; Obach, R. S. Commentary on metabolites in safety testing. Seeing through the mist: Abundance versus percentage Drug Metab. Dispos. 2005, 33 (10) 1409-1417
18. Smith, D. A.; Obach, R. S. Metabolites and Safety: What Are the Concerns, and How Should We Address Them? Chem. Res. Toxicol. 2006, 19 (12) 1570-1579
19. Smith, D. A.; Obach, R. S. Metabolites in Safety Testing (MIST): Considerations of Mechanisms of Toxicity with Dose, Abundance, and Duration of Treatment Chem. Res. Toxicol. 2009, 22 (2) 267-279
20. Smith, D. A.; Obach, R. S. Metabolites: have we MIST out the importance of structure and physicochemistry Bioanalysis 2010, 2 (7) 1223-1233
21. Smith, D. A.; Jones, B. C. Speculations on the substrate-structure relationship (SSAR) of cytochrome P450 enzymes Biochem. Pharmacol. 1992, 44 (11) 2089-2098
22. Smith, D. A.; Ackland, M. J.; Jones, B. C. Properties of cytochrome P450 isoenzymes and their substrates. Part 1: active site characteristics Drug Discovery Today 1997, 2 (10) 406-414
23. Smith, D. A.; Ackland, M. J.; Jones, B. C. Properties of cytochrome P450 isoenzymes and their substrates. Part 1: properties of cytochrome P450 substrates Drug Discovery Today 1997, 2 (11) 479-486
24. Smith, D. A.; Dalvie, D. Why do metabolites circulate Xenobiotica 2012, 42 (1) 107-106
25. Smith, D. A.; Harrison, A.; Morgan, P. Multiple Factors Govern the Association between Pharmacology and Toxicity in a Class of Drugs: Toward a Unification of Class Effect Terminology Chem. Res. Toxicol. 2011, 24 (4) 463-474
26. Treiber, A.; Schneiter, R.; Delahaye, S.; Clozel, M. Inhibition of organic anion transporting polypeptide-mediated hepatic uptake is the major determinant in the pharmacokinetic interaction between bosentan and cyclosporin a in the rat J. Pharmacol. Exp. Ther. 2003, 308 (3) 1121-1129
27. Saito, H.; Osumi, M.; Hirano, H.; Shin, W.; Nakamura, R.; Ishikawa, T. Technical pitfalls and improvements for high-speed screening and QSAR analysis to predict inhibitors of the human bile salt expert pump (ABCB11/BSEP) AAPS J. 2009, 11 (3) 581-589
28. Thompson, R. A.; Isin, E. M.; Li, Y.; Weidolf, L.; Page, K.; Wilson, I.; Swallow, S.; Middleton, B.; Stahl, S.; Foster, A. J.; Dolgos, H.; Weaver, R.; Kenna, J. G. In Vitro Approach to Assess the Potential for Risk of Idiosyncratic Adverse Reactions Caused by Candidate Drugs Chem. Res. Toxicol. 2012, 25 (8) 1616-1632
29. Smith, D. A. Dogma driven science, the need to establish a common base line Chem.-Biol. Interact. 2009, 179 (1) 68-70
30. Smith, D. A. Do prodrugs deliver Curr. Opin. Drug Discovery Dev. 2007, 10 (5) 550-559
31. Sievers, E.; Linenberger, M. Mylotarg: antibody-targeted chemotherapy comes of age Oncology 2001, 13 (6) 522-527
32. Tuma, R. S. Mylotarg Revisited: Withdrawal Will Have Major Impact on Patients, Some Leukemia Experts Say Oncol. Times 2010, 32 (19) 11-13